Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial

Postmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone loss (AIBL) and fractures. In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred and three postmenopausal women with early breast cancer (EBC) were enrol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Bone Oncol
Autors principals: Lomax, Anna J., Yee Yap, Saw, White, Karen, Beith, Jane, Abdi, Ehtesham, Broad, Adam, Sewak, Sanjeev, Lee, Chooi, Sambrook, Philip, Pocock, Nicholas, Henry, Margaret J., Yeow, Elaine G., Bell, Richard
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723379/
https://ncbi.nlm.nih.gov/pubmed/26909285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2013.08.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars